Form 4: Immunocore R&D Head Sells Shares After Option Exercise

Immunocore Holdings plc's Head of R&D, David M. Berman, executed pre-planned sales of ordinary shares following the exercise of employee stock options.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, engaged in transactions involving the company's ordinary shares.
• On November 24, 2025, Berman exercised options to acquire 100 ordinary shares at $17.46 per share and subsequently sold these 100 shares at $40.00 per share.
• On November 25, 2025, Berman exercised options to acquire 18,020 ordinary shares at $17.46 per share and subsequently sold these 18,020 shares at a weighted average price of $40.03 per share, with prices ranging from $40.00 to $40.17.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 9, 2025.
• Following these transactions, Berman beneficially owns 118,670 employee share options exercisable at $17.46, expiring on September 12, 2028.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transactions represent routine insider profit-taking under a pre-arranged plan, which is generally expected. While insider selling can sometimes be viewed negatively, the context of option exercise and a 10b5-1 plan mitigates this concern. The executive still retains a significant number of options.

Positives

• The Head of R&D realized a significant profit by exercising options at $17.46 and selling shares at an average price of approximately $40.00.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than opportunistic trading based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although the profit-taking motive is clear here.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider selling as a minor negative, but the 10b5-1 plan context and the executive's continued holding of options should limit significant concern. The transactions demonstrate the value of the company's stock options.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (exercise of options and subsequent sale of shares) executed under a pre-planned Rule 10b5-1 trading plan. Such transactions are common for executives managing their equity compensation and do not typically signal a change in the company's fundamental outlook or performance. The executive still retains a substantial number of unexercised options, indicating continued alignment with shareholder interests. Therefore, this filing alone does not warrant a change in investment recommendation; a "hold" stance remains appropriate, pending further company-specific or market-wide developments.

Keywords

Immunocore Holdings, IMCR, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, David M. Berman, Share Sale, Employee Stock Options